CuraScript SD by Evernorth

Overview

CuraScript SD by Evernorth is the specialty distribution arm of Evernorth, the health-services division of The Cigna Group. It distributes provider-administered biologics, branded drugs, generics, vaccines, infused medications, and ancillary supportive-care products to physicians’ offices, clinics, hospitals, surgery centers, IDNs, and other clinical settings. Buyers searching CuraScript Specialty Distribution, Express Scripts CuraScript SD, or Cigna CuraScript SD should evaluate CuraScript SD by Evernorth as the active brand.

CuraScript SD is a specialty distributor, not a PBM, hub-services vendor, or specialty pharmacy. It is most relevant when a launch needs buy-and-bill channel access, GPO-connected provider supply, overnight U.S. distribution, and specialty handling. The Evernorth parent is material because it sits alongside Accredo specialty pharmacy and Express Scripts PBM operations; manufacturers should keep distribution, dispensing, and PBM roles contractually separate during diligence.

Drug Supply Chain Capability Model

The framework below standardizes how Rx Almanac evaluates drug-supply-chain capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, CuraScript SD by Evernorth is evaluated as specialty distribution arm of Evernorth, the health-services division of The Cigna Group.

Capability	Buyer should compare	CuraScript SD by Evernorth readout
Wholesale and specialty distribution access	Wholesale scale, specialty distribution, limited distribution, provider/pharmacy reach, and trade partner relationships.	Core fulfillment handoff. CuraScript SD is a specialty distributor for provider-administered pharmaceuticals and supplies, with a contracted supplier role with most major GPOs. Differentiator with governance questions. Newark co-locates CuraScript SD and Accredo operations, but buyers should keep distribution, specialty pharmacy, and PBM roles contractually distinct.
3PL warehousing and order fulfillment	Warehousing, pick/pack/ship, order management, service levels, launch stocking, and direct fulfillment.	Documented but scope-specific. Parent-company filings describe CuraScript SD as using its distribution platform as a 3PL provider for several pharmaceutical companies; validate exact scope in RFP.
Cold chain and specialty handling	Temperature-controlled storage, refrigerated/frozen shipping, biologics, specialty products, and excursion procedures.	Core complex-product handling. Public materials and filings position CuraScript SD around specialty pharmaceuticals, infused products, and typical overnight U.S. shipping from a four-distribution-center network.
DSCSA, serialization, and compliance controls	Serialization, tracing, verification, EPCIS, licensure, audit readiness, and regulatory compliance.	Not the main buying reason for CuraScript SD by Evernorth; validate only if the SOW includes dscsa, serialization, and compliance controls.
340B, returns, reverse logistics, or leakage controls	Returns, recalls, 340B controls, diversion monitoring, credit recovery, product destruction, and leakage management.	Not the main buying reason for CuraScript SD by Evernorth; validate only if the SOW includes 340b, returns, reverse logistics, or leakage controls.
Inventory visibility and trade reporting	Inventory data, demand signals, EDI/API feeds, order status, channel analytics, and manufacturer reporting.	Ordering workflow. Provider materials emphasize flexible ordering, EDI-enabled processing, simplified billing, and support for practices trying to limit on-hand inventory.

Buyer Fit

• Commercial fit trigger: Provider-administered specialty products, rare/orphan therapies, infused/injectable medications, retina/ophthalmology, orthopedics, and multi-specialty clinic channels where buy-and-bill execution matters.
• Manufacturer use case: Consider CuraScript SD when the launch needs specialty distribution plus selected 3PL support, not when the primary problem is patient hub services, adherence coaching, or payer-contract strategy.
• Provider channel fit: Stronger for clinics, hospitals, surgery centers, IDNs, and GPO-linked provider sites than for direct-to-patient dispensing.
• Governance fit: The Evernorth stack can be useful, but RFPs should define whether CuraScript SD, Accredo, Express Scripts, or another Evernorth entity owns each obligation.

Differentiators

• Four-distribution-center national reach: Current parent-company materials describe a four-distribution-center network that ships most products overnight in the United States.
• Provider-administered focus: The operating model is built around office or clinic administration of high-cost specialty pharmaceuticals rather than retail or mail-order dispensing.
• GPO supplier role: CuraScript SD is described as a contracted supplier with most major group purchasing organizations.
• Accredo co-location: Evernorth’s Newark, Delaware facility brings Accredo specialty pharmacy capabilities and CuraScript SD distribution capabilities under one roof.
• Practice support: Disease-state and territory-specialized account teams support ordering, billing, EDI, and inventory workflows for provider practices.

RFP Questions

• Which products will CuraScript SD support as distributor, 3PL, or both, and which responsibilities stay with the manufacturer?
• Which GPO contracts, provider specialties, and care settings are in scope for launch access?
• What order, inventory, EDI, chargeback, returns, temperature, and exception data will the manufacturer receive?
• How are Accredo and Express Scripts separated from CuraScript SD in contracts, data flows, and governance?
• What service-level commitments apply to overnight shipment, cold-chain excursions, recalls, shortages, and allocation events?

Recent Activity

• 2025: Evernorth opened a Newark, Delaware specialty care facility co-locating Accredo Specialty Pharmacy and CuraScript SD operations.
• 2025: The Cigna Group’s annual report described CuraScript SD as operating four distribution centers and shipping most products overnight in the United States.
• 2025: GSK and ViiV listed CuraScript SD as an authorized wholesaler / distributor of record (November 2025 list).
• 2025-2026: CuraScript SD materials continue to emphasize practice-facing support, dedicated account teams, ordering flexibility, EDI, and provider-administered specialty distribution.